"All Eyes on wAIHA Phase 3 Data Next Month" - H.C. Wainwright Reiterates Buy Rating, $11 Price Target on Rigel Pharmaceuticals (RIGL)
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $11.00 price target on Rigel Pharmaceuticals (NASDAQ: RIGL), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
